You searched for "age"

2071 results found

Case series of posterior scleritis

This report aimed to facilitate the correct diagnosis of posterior scleritis, a condition which is usually overlooked or misdiagnosed. Electronic health records of 31 patients with posterior scleritis were analysed and compared to a group with isolated anterior scleritis of...

Long-term corneal crosslinking results in paediatric eyes

This prospective longitudinal study examined patients 18 years of age or less with progressive keratoconus, who underwent corneal crosslinking and completed 10 years of follow-up. Crosslinking protocol involved removal of epithelium, 10 minutes of riboflavin soaking, followed by 30 minutes...

Direct endoscopic probing for congenital lacrimal duct obstruction

The most common treatment for congenital lacrimal duct obstruction (CLDO) is probing, which is traditionally a blind procedure. Previous literature reports success rates between 78-92%. The authors of this retrospective non comparative case series reviewed the success rates of probing...

Prostaglandin levels in femto cataract surgery

Following previous reports of pupil size decrease after femtosecond treatment, the authors compare levels of prostaglandins in patients undergoing femtosecond assisted cataract surgery with those having routine cataract surgery. Patients with inflammatory eye disease, previous trauma surgery, age-related macular degeneration...

Outcomes of corneal cross-linking in paediatric patients compared to fellow untreated eyes

This retrospective cohort study evaluated long-term visual, refractive, topographic and safety outcomes of corneal cross-linking (CXL) in patients younger than 18-years-old with keratoconus. The study included all consecutive paediatric patients who underwent epithelium-off CXL treatment for keratoconus at the study...

Simultaneous vs. alternate PCT disparity in XT

The authors quantified the relationship between simultaneous prism and cover test (SPCT) and alternate prism and cover test (APCT) alignment in patients with measures at the same visit after surgery for exotropia. This was a retrospective study of 955 patients...

PRN Ranibizumab verses continuous aflibercept in UK clinical practice

This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Cataract surgery in patients with retinitis pigmentosa

Retinitis pigmentosa (RP) is the commonest inherited cause of retinal degeneration. Posterior subcapsular cataract (PSC) develops in 41% to 90% of these patients by age 40 years. In this retrospective study, the authors have evaluated surgical outcomes in patients with...

Endoscopic assisted probing for congenital nasolacrimal duct obstruction

In this retrospective study authors compare the success rate of nasal endoscopic-assisted probing between younger (three years and below) and older (three years and above) children with membranous nasolacrimal duct obstruction and its correlation with the thickness of the membrane...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...